M&A Deal Summary |
|
|---|---|
| Date | 2008-12-10 |
| Target | Dow Pharmaceutical Sciences |
| Sector | Life Science |
| Buyer(s) | Bausch Health |
| Sellers(s) |
Galen Partners
EW Healthcare Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 285M USD |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 20,270 |
| Revenue | 9.6B USD (2024) |
Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 36 |
| Sector: Life Science M&A | 3 of 22 |
| Type: Add-on Acquisition M&A Deals | 3 of 26 |
| State: California M&A | 3 of 7 |
| Country: United States M&A | 3 of 23 |
| Year: 2008 M&A | 2 of 2 |
| Size (of disclosed) | 16 of 28 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-09-17 |
Coria Laboratories
Aliso Viejo, California, United States Coria Laboratories Ltd. specializing in research, development and marketing of branded prescription and over-the-counter dermatology products. |
Buy | $95M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-07-29 |
Tecnofarma S.A. de C.V.
Iztacalco, Mexico Tecnofarma is a producer of generic pharmaceuticals to the government and private label markets. |
Buy | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1990 |
| PE ASSETS | 1.0B USD |
| Size | Large |
| Type | Sector Focused |
Galen Partners is a private equity firm that targets investments in the healthcare industry. Areas within healthcare that Galen will consider include medical devices & technology, specialty pharmaceuticals, and information technology/services. Galen typically invests between $10 and $30 million per transaction in companies with a proprietary product or service that have attained revenues above $10 million. Prospective transactions include growth equity investments, complete buyouts, family business or other recapitalizations, going-private transactions, roll-overs of a portion of existing equity, and management buyouts. Galen Partners was formed in 1990 and is based in Stamford, Connecticut.
| DEAL STATS | # |
|---|---|
| Overall | 11 of 26 |
| Sector: Life Science M&A | 2 of 3 |
| Type: Add-on Acquisition M&A Deals | 10 of 22 |
| State: California M&A | 3 of 6 |
| Country: United States M&A | 11 of 26 |
| Year: 2008 M&A | 3 of 3 |
| Size (of disclosed) | 4 of 11 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-06-05 |
Specialized Health Products Intl
Bountiful, Utah, United States Specialized Health Products Intl, Inc.,is a designer, developer, manufacturer and licenser of cost-effective, innovative safety healthcare products. |
Sell | $68M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-07-01 |
PeriGen
Cranbury, New Jersey, United States PeriGen is a provider of fetal monitoring and surveillance software systems for perinatal clinicians. PeriGen is based in Cranbury, New Jersey. |
Buy | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1985 |
| PE ASSETS | 3.0B USD |
| Size | Large |
| Type | Sector Focused |
Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.
| DEAL STATS | # |
|---|---|
| Overall | 14 of 53 |
| Sector: Life Science M&A | 6 of 17 |
| Type: Add-on Acquisition M&A Deals | 8 of 34 |
| State: California M&A | 5 of 17 |
| Country: United States M&A | 13 of 46 |
| Year: 2008 M&A | 5 of 5 |
| Size (of disclosed) | 9 of 22 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-08-05 |
Iomai
Gaithersburg, Pennsylvania, United States Developed a method to safely and more effectively deliver vaccines through the use of a skin patch and without injections. |
Sell | €75M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-02-04 |
Symphogen AS
Ballerup, Denmark Symphogen AS is a polyclonal antibody technology that provides a totally new, innovative class of biopharmaceuticals for treating serious human diseases. Symphogen was founded in 2000 and is based in Ballerup, Denmark. |
Buy | - |
